In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Silexion Therapeutics, with a price target of $12.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Naz Rahman has given his Buy rating due to a combination of factors surrounding Silexion Therapeutics’ recent developments and future potential. The company has received positive feedback from German regulatory authorities regarding its Phase 2/3 clinical trial design for SIL-204, which is a promising step forward. This feedback allows Silexion to proceed with filing a Clinical Trial Application in Germany, with expectations to initiate the trial in the first half of 2026. Additionally, Silexion plans to submit regulatory applications in Israel by the end of 2025, with both trials anticipated to start by mid-2026.
The analyst also highlights the significant unmet medical need in pancreatic cancer, which SIL-204 aims to address, presenting a substantial market opportunity. Previous pre-clinical data have shown positive results for SIL-204, supporting its potential efficacy. With a market cap under $10 million, Rahman believes that Silexion is currently undervalued and overlooked by investors, reinforcing the Buy recommendation.
SLXN’s price has also changed dramatically for the past six months – from $0.960 to $2.550, which is a 165.62% increase.